Twist Bioscience (NASDAQ:TWST) Stock Rating Upgraded by ValuEngine

Twist Bioscience (NASDAQ:TWST) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.

TWST has been the topic of several other reports. Evercore ISI initiated coverage on Twist Bioscience in a research note on Friday, May 31st. They set an “outperform” rating and a $26.66 price target on the stock. Zacks Investment Research lowered Twist Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Twist Bioscience currently has an average rating of “Buy” and an average target price of $26.55.

Shares of Twist Bioscience stock traded down $2.49 during trading on Thursday, reaching $29.95. The company’s stock had a trading volume of 449,306 shares, compared to its average volume of 286,317. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.27 and a current ratio of 6.51. The stock has a fifty day moving average price of $29.47. Twist Bioscience has a one year low of $12.38 and a one year high of $35.95.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $13.60 million during the quarter, compared to analyst estimates of $12.51 million. Research analysts forecast that Twist Bioscience will post -3.65 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Twist Bioscience by 9.7% during the first quarter. JPMorgan Chase & Co. now owns 1,050,458 shares of the company’s stock valued at $24,350,000 after acquiring an additional 93,144 shares during the period. Emerald Advisers LLC grew its stake in shares of Twist Bioscience by 146.5% in the 2nd quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after purchasing an additional 344,463 shares during the period. Emerald Mutual Fund Advisers Trust grew its stake in shares of Twist Bioscience by 156.0% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after purchasing an additional 319,373 shares during the period. BlackRock Inc. bought a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $7,782,000. Finally, ARK Investment Management LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $6,202,000. Hedge funds and other institutional investors own 18.50% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Story: What is meant by holder of record?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.